Ypke Oosterhout is the founder of Xenikos. Xenikos has raised $30M in total funding. Latest round: Series B. Backed by Medicxi, RA Capital Management.
Ypke van Oosterhout is the Chief Executive Officer of Xenikos, a clinical-stage biopharmaceutical company based in Nijmegen, Netherlands. Xenikos is developing a novel therapy, T-Guard, for treating acute graft-versus-host disease (aGVHD). The company secured USD 30 million in Series B financing to advance the development of T-Guard, including conducting Phase 3 clinical trials and preparing for market approval.
Full founder directory · Investor directory · Company funding database · Fundraising library